In this large multicenter study, we investigated how demographic (age and sex), clinical (MMSE), genetic (APOE genotype), and imaging/CSF (AD-signature cortical thickness, global WMH volumes, and Aβ status) variables were associated with tau PET status defined using previously established quantitative thresholds for [18F]flortaucipir and [18F]RO948. The gene discussed is MAPT; the disease is Alzheimer disease.